IM Cannabis (NASDAQ:IMCC – Get Free Report) and Indivior (OTCMKTS:INVVY – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings for IM Cannabis and Indivior, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| Indivior | 0 | 0 | 1 | 0 | 3.00 |
Indivior has a consensus price target of $50.00, indicating a potential upside of 128.88%. Given Indivior’s stronger consensus rating and higher probable upside, analysts clearly believe Indivior is more favorable than IM Cannabis.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| Indivior | N/A | N/A | N/A |
Insider & Institutional Ownership
7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 0.1% of Indivior shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
IM Cannabis has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
Earnings and Valuation
This table compares IM Cannabis and Indivior”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
| Indivior | $791.00 million | 3.81 | $205.00 million | $1.05 | 20.81 |
Indivior has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Summary
Indivior beats IM Cannabis on 11 of the 14 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About Indivior
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
